Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy Peregrine Pharmaceuticals (PPHM)?

There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each year by hiring the best and the brightest to do research on stocks, including small cap stocks that big brokerage houses simply don’t cover. Because of Carl Icahn and other elite funds’ exemplary historical records, we pay attention to their small cap picks. In this article, we use hedge fund filing data to analyze Peregrine Pharmaceuticals (NASDAQ:PPHM).

Hedge fund interest in Peregrine Pharmaceuticals (NASDAQ:PPHM) shares was flat at the end of last quarter, even though the stock lost 21% during the quarter. The company is expected to increase its revenue, although its bottom line estimates are deep in the red territory. Let’s take a closer look at which funds decided to stick to their holdings in the company. In addition, at the end of this article we will also compare PPHM to other stocks, including Black Diamond Inc (NASDAQ:BDE), China XD Plastics Co Ltd (NASDAQ:CXDC), and Enzymotec Ltd (NASDAQ:ENZY) to get a better sense of its popularity.

Follow Avid Bioservices Inc. (NASDAQ:CDMO)
Trade (NASDAQ:CDMO) Now!

To the average investor, there are many tools market participants have at their disposal to grade publicly traded companies. Some of the most under-the-radar tools are hedge fund and insider trading activity. We have shown that, historically, those who follow the best picks of the elite fund managers can outperform the market by a solid margin (see the details here).

Now, let’s take a look at the new action surrounding Peregrine Pharmaceuticals (NASDAQ:PPHM).

What does the smart money think about Peregrine Pharmaceuticals (NASDAQ:PPHM)?

At the end of the third quarter, a total of 7 of the hedge funds tracked by Insider Monkey held long positions in this stock. Among them, Millennium Management, led by Israel Englander, holds the number one position in Peregrine Pharmaceuticals (NASDAQ:PPHM), valued at $0.9 million and comprising less than 0.1%% of its 13F portfolio. The second largest stake is held by Iguana Healthcare Management, managed by Stuart Weisbrod, which holds a $0.4 million position; 0.1% of its 13F portfolio is allocated to the stock. Some other members of the smart money with similar optimism encompass Jim Simons’ Renaissance Technologies, Hal Mintz’s Sabby Capital and Cliff Asness’ AQR Capital Management.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.